Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACS 04: Docetaxel/Epirubicin vs FEC and Trastuzumab in Node-Positive Breast Cancer
NCT00054587Phase 3Completed
- Sponsor
- Unicancer
- Start
- Jun 2001
- Primary completion
- Jun 2009
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, trastuzumab in breast cancer, sponsored by Unicancer. Started Jun 2001; status: completed.
02
Drugs
docetaxeltrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00054587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054587.